Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against Trypanosoma brucei

  • RSC Med Chem. 2020 May 18;11(8):885-895. doi: 10.1039/d0md00057d.
Zhongsheng Zhang  1 Ximena Barros-Álvarez  1 J Robert Gillespie  2 Ranae M Ranade  2 Wenlin Huang  1 Sayaka Shibata  1 Nora M R Molasky  2 Omeed Faghih  2 Aisha Mushtaq  2 Robert K M Choy  3 Eugenio de Hostos  3 Wim G J Hol  1 Christophe L M J Verlinde  1 Frederick S Buckner  2 Erkang Fan  1
Affiliations
  • 1. Department of Biochemistry , University of Washington , Seattle , WA 98195 , USA . Email: [email protected].
  • 2. Department of Medicine , Division of Allergy & Infectious Disease , Center for Emerging & Re-emerging Infectious Disease (CERID) , University of Washington , Seattle , WA 98109 , USA . Email: [email protected].
  • 3. PATH , San Francisco , CA 94108 , USA.
Abstract

Based on crystal structures of Trypanosoma brucei methionyl-tRNA synthetase (TbMetRS) bound to inhibitors, we designed, synthesized, and evaluated two series of novel TbMetRS inhibitors targeting this Parasite enzyme. One series has a 1,3-dihydro-imidazol-2-one containing linker, the Other has a rigid fused aromatic ring in the linker. For both series of compounds, potent inhibition of Parasite growth was achieved with EC50 < 10 nM and most compounds exhibited low general toxicity to mammalian cells with CC50s > 20 000 nM. Selectivity over human mitochondrial methionyl tRNA synthetase was also evaluated, using a cell-based mitochondrial protein synthesis assay, and selectivity in a range of 20-200-fold was achieved. The inhibitors exhibited poor permeability across the blood brain barrier, necessitating future efforts to optimize the compounds for use in late stage human African trypanosomiasis.